CORRECTING and REPLACING -- Cempra to Present at Upcoming Investor Conferences

Morristown, New Jersey, UNITED STATES

CHAPEL HILL, N.C., Feb. 08, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cempra, Inc. (Nasdaq:CEMP), the Leerink Partners conference should be noted as located at the Lotte New York Palace, not at the Waldorf Astoria as previously stated. The corrected release follows.

Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in three upcoming investor conferences.

  • Leerink Partners 6th Annual Global Healthcare Conference, Lotte New York Palace, New York, February 15, 2017 at 10:00 a.m. ET
  • Cowen and Company 37th Annual Healthcare Conference, Marriott Copley Place, Boston, March 6, 2017 at 4:00 p.m. ET
  • Raymond James 38th Annual Institutional Investors Conference, JW Marriott Grande Lakes, Orlando, March 7, 2017 at 10:30 a.m. ET

A live audio webcast and archive of the presentations will be available on the company website at Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.

About Cempra, Inc.

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra’s two lead product candidates are currently in advanced clinical development. Solithromycin has been evaluated in two Phase 3 clinical trials for community-acquired bacterial pneumonia.  Cempra is currently seeking approval for both intravenous and oral capsule formulations from the U.S. Food and Drug Administration and the European Medicines Agency. Solithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use and has commenced enrollment in a global Phase 2/3 trial to evaluate the safety and efficacy of solithromycin versus standard of care antibiotics in children and adolescents from two months to 17 years of age. Fusidic acid is Cempra's second product candidate, which has completed enrollment of an initial Phase 3 trial comparing fusidic acid to linezolid in patients with acute bacterial skin and skin structure infections (ABSSSI). Cempra also has an ongoing exploratory study of fusidic acid for chronic oral treatment of refractory infections in bones and joints.

Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is also studying solithromycin for ophthalmic conditions and has synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit


Contact Data